



Consolidated Financial Results
for the Nine Months Ended September 30, 2021
[IFRS]

November 10, 2021

Company name: Nissha Co., Ltd.
 Stock exchange listing: Tokyo Stock Exchange
 Code number: 7915
 URL: <https://www.nissha.com/english>
 Representative: Junya Suzuki, Chairman of the Board, President and CEO
 Contact: Hitoshi Koya, Senior Vice President, CFO, Corporate officer
 Phone: +81-75-811-8111
 Scheduled date of filing quarterly securities report: November 12, 2021
 Scheduled date of commencing dividend payments: —
 Availability of supplementary briefing material on quarterly financial results: Available
 Schedule of quarterly financial results briefing session: Scheduled (for institutional investors)

(Amounts of less than one million yen are rounded down)

1. Consolidated Financial Results for the Nine Months Ended September 30, 2021 (January 1, 2021 to September 30, 2021)

(1) Consolidated Operating Results (cumulative) (% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit		Profit attributable to owners of parent		Total comprehensive income	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Nine months ended September 30, 2021	145,532	13.0	15,443	295.6	16,903	332.3	14,503	257.6	14,517	257.9	16,138	267.1
Nine months ended September 30, 2020	128,785	1.9	3,903	791.3	3,910	—	4,055	—	4,055	—	4,396	—

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Nine months ended September 30, 2021	291.39	289.94
Nine months ended September 30, 2020	81.20	79.15

(Note) The Company finalized the provisional accounting treatment pertaining to business combinations in the fiscal year ended December 31, 2020, and reflected the details of the finalization of the provisional accounting treatment on figures related to the corresponding period of the previous year.

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
	Million yen	Million yen	Million yen	%
As of September 30, 2021	205,250	96,437	96,454	47.0
As of December 31, 2020	199,726	82,081	82,083	41.1

2. Dividends

	Annual dividends				
	1st quarter-end	2nd quarter-end	3rd quarter-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended December 31, 2020	—	15.00	—	15.00	30.00
Fiscal year ending December 31, 2021	—	15.00	—		
Fiscal year ending December 31, 2021 (Forecast)				25.00	40.00

(Notes)

1. Revision of cash dividend forecast: Yes
2. Breakdown of the year-end dividend for the fiscal year ending December 31, 2021: Ordinary dividend of ¥15 and special dividend of ¥10

3. Consolidated Financial Results Forecast for the Fiscal Year Ending December 31, 2021 (January 1, 2021 to December 31, 2021)

(% indicates changes from the previous corresponding period)

	Net sales		Operating profit		Profit before tax		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	186,500	3.6	17,000	133.2	18,000	155.3	15,200	115.0	305.30

(Note) Revision of consolidated financial results forecast: No

Contents of Appendix

1. Qualitative Information on Consolidated Financial Results for the Period under Review	2
(1) Explanation of operating results	2
(2) Explanation of financial position	3
(3) Explanation of consolidated operating results forecast and other forecast information	4
2. Condensed Consolidated Financial Statements and Principal Notes	5
(1) Condensed consolidated statements of financial position.....	5
(2) Condensed consolidated statements of profit or loss and comprehensive income.....	7
Condensed consolidated statements of profit or loss	7
Condensed consolidated statements of comprehensive income	8
(3) Condensed consolidated statements of changes in equity	9
(4) Condensed consolidated statements of cash flows	10
(5) Notes to condensed consolidated financial statements	12
(Notes to going concern assumptions).....	12
(Segment information).....	12

1. Qualitative Information on Consolidated Financial Results for the Period under Review

The provisional accounting treatment pertaining to the business combinations with AR Metallizing GmbH (renamed from Eurofoil Paper Coating GmbH on April 30, 2020) on January 31, 2020 was finalized at the end of the previous fiscal year. Accordingly, amounts for the previous corresponding nine months used for the comparison reflect the adjustments for the finalization of provisional accounting treatments.

In addition, from the first quarter ended March 31, 2021, the Company has changed its business segments stated as reportable segments, and made comparisons and analysis based on the categories following the change. For details, please see “Segment information” under “(5) Notes to condensed consolidated financial statements.”

(1) Explanation of operating results

The Group’s Mission is to use the diverse talents of its people and core technologies as an engine for growth to create highly competitive, feature-rich products and services that realize customer value and contribute to better lives for all. Guided by this Mission, we established our Sustainability Vision as our long-term vision for 2030, and reflecting backward, formulated a strategy as set forth in our 7th Medium-term Business Plan to achieve our medium-term vision for 2023. Under the 7th Medium-term Business Plan, we aim to construct a foundation for growth by fully utilizing the global business bases we have acquired and built so far and maximizing their synergies.

During the nine months ended September 30, 2021, global economic environment was severe due to the remaining impact of the novel coronavirus disease (COVID-19), but the economic conditions trended toward recovery. The United States and Europe made steady headway in economic recovery, although the impact of shortages of raw materials and soaring labor cost became apparent. In China, economic conditions continued to recover gradually. In Japan, trends toward economic recovery were steady owing to rising exports with improvements in overseas economy, but the pace of recovery slowed down due to recurrent cases of COVID-19 and constraints on supply due to shortage of semiconductor products, etc.

Under these conditions, with regard to financial results for the nine months ended September 30, 2021, demand remained generally firm in the Devices and the Industrial Materials segments, despite some fluctuations for certain products. In the Medical Technologies segment, trends toward recovery in product demand, which had been decreased due to COVID-19, continued. Buoyed by firm product demand, an efficient circulation of production and sales was maintained, and operating profit improved significantly year on year.

As a result, regarding the financial results for the nine months ended September 30, 2021, net sales were ¥145,532 million (an increase of 13.0% as compared to the same period of the previous year). Operating profit was ¥15,443 million (an increase of 295.6% as compared to the same period of the previous year). Profit attributable to owners of parent was ¥14,517 million (an increase of 257.9% as compared to the same period of the previous year).

Following is an overview by business segment.

Industrial Materials

In the Industrial Materials segment, we mainly offer proprietary technologies that enable to create added value on the surfaces of various materials. IMD, IML, and IME, which facilitate simultaneous in-mold decoration, design and function adding of plastic products, are extensively adopted in mobility components and home appliances in global markets. Also, our metallized paper, which unites the properties of metallic luster and printing friendliness, has the largest market share in the industry as sustainable materials for beverages and foods on a global basis.

During the nine months ended September 30, 2021, net sales increased compared to the same period of the previous year thanks to strong demand as a whole, despite having been affected partially by adjustments due to shortage of semiconductor products, etc. in the second half of the fiscal year. In addition to the impact of such product demand, the improvements in

profit structure substantially improved operating profit over the same period of the previous year.

As a result, segment sales for the nine months ended September 30, 2021 were ¥44,291 million (an increase of 26.0% as compared to the same period of the previous year). Segment profit (operating profit) was ¥3,969 million (an increase of 801.6% as compared to the same period of the previous year).

Devices

In the Devices segment, we produce components and module products that pursue precision and functionality. Our main products, film-based Touch Sensors are widely adopted mainly in tablets, smartphones, portable game players, industrial equipment (logistics related), mobility components, etc. in global markets. In addition, we offer gas sensors that can detect gas conditions, along with other products.

During the nine months ended September 30, 2021, while demand for products for smartphones was on a downturn trend in the second half of the fiscal year, a strong product demand continued for tablets. Production leveling due to sustained product demand and improvements in profit structure also substantially expanded operating profit over the same period of the previous year.

As a result, segment sales for the nine months ended September 30, 2021 were ¥78,071 million (an increase of 7.3% as compared to the same period of the previous year). Segment profit (operating profit) was ¥12,621 million (an increase of 108.7% as compared to the same period of the previous year).

Medical Technologies

The Medical Technologies segment is a business segment that offers high-quality and value-added products in medical devices and other related markets to contribute to healthy and affluent life. The segment provides contract development manufacturing services for major medical device manufacturers on a global basis with products such as surgical instruments for minimal invasive treatments and medical wearable sensors used for a wide range of conditions, primarily heart disease. In addition to these, the segment currently manufactures and sells its own brand products to medical institutions.

During the nine months ended September 30, 2021, product demand continued to recover, which had been decreased due to COVID-19, and net sales steadily improved year on year. Meanwhile, soaring raw materials and labor costs in the United States put pressure on profitability, and operating profit was roughly the same as that in the same period of the previous year.

As a result, segment sales for the nine months ended September 30, 2021 were ¥17,776 million (an increase of 15.8% as compared to the same period of the previous year). Segment profit (operating profit) was ¥740 million (an increase of 9.2% as compared to the same period of the previous year).

(2) Explanation of financial position

1) Assets, liabilities and equity

Total assets at the end of the third quarter ended September 30, 2021 increased by ¥5,524 million from the end of the previous year (the fiscal year ended December 31, 2020) to ¥205,250 million.

Current assets increased by ¥7,534 million from the end of the previous year to ¥100,159 million. This was mainly because a ¥14,088 million increase of cash and cash equivalents and a ¥2,380 million increase of inventories outweighed a ¥8,727 million decrease of trade and other receivables.

Non-current assets decreased by ¥2,009 million from the end of the previous year to ¥105,091 million. This was mainly because a ¥3,527 million decrease of property, plant and equipment, and a ¥696 million decrease of other financial assets mainly due to a change in fair value of financial assets measured at fair value through other comprehensive income

outweighed a ¥1,189 million increase of goodwill due to the impact of foreign exchange conversion and a ¥983 million increase of right-of-use assets.

Total liabilities at the end of the third quarter ended September 30, 2021 decreased by ¥8,831 million from the end of the previous year to ¥108,812 million.

Current liabilities decreased by ¥23,501 million from the end of the previous year to ¥60,762 million. This was mainly because of a ¥9,068 million decrease of trade and other payables and a ¥12,254 million decrease of bonds and borrowings.

Non-current liabilities increased by ¥14,669 million from the end of the previous year to ¥48,050 million. This was mainly because of a ¥14,452 million increase of bonds and borrowings resulting from issuance of new bonds.

Total equity at the end of the third quarter ended September 30, 2021 increased by ¥14,356 million from the end of the previous year to ¥96,437 million. This was mainly because of a ¥12,941 million increase of retained earnings due to the recording of profit attributable to owners of parent and a ¥1,714 million increase of other components of equity due to the impact of foreign exchange conversion.

2) Cash flows

The balance of cash and cash equivalents (the “funds”) on a consolidated basis at the end of the nine months ended September 30, 2021 was ¥39,155 million, an increase of ¥14,088 million compared to the end of the previous year.

The following describes the conditions of each cash flow and the underlying causes for the nine months ended September 30, 2021.

(Net Cash Provided by (Used in) Operating Activities)

Funds provided by operating activities amounted to ¥18,047 million (an increase of 396.3% as compared to the same period of the previous year). This was mainly because there were ¥16,903 million of profit before tax and ¥6,920 million of depreciation and amortization, although there was ¥3,651 million of income taxes paid.

(Net Cash Provided by (Used in) Investing Activities)

Funds used in investing activities amounted to ¥4,263 million (¥1,835 million provided in the same period of the previous year). This was mainly because of ¥4,356 million of purchase of property, plant and equipment.

(Net Cash Provided by (Used in) Financing Activities)

Funds used in financing activities amounted to ¥1,860 million (a decrease of 8.2% as compared to the same period of the previous year). This was mainly because there were ¥8,013 million of repayments of short-term borrowings, ¥4,813 million of repayments of long-term borrowings, ¥2,840 million of redemption of bonds, ¥1,490 million of dividends paid to owners of parent, and ¥1,404 million of repayments of lease liabilities, although there were ¥9,945 million of proceeds from issuance of bonds and ¥6,696 million of proceeds from long-term borrowings.

(3) Explanation of consolidated operating results forecast and other forecast information

The consolidated financial forecasts for the fiscal year ending December 31, 2021 remain unchanged from the forecasts announced on August 5, 2021.

2. Condensed Consolidated Financial Statements and Principal Notes
(1) Condensed consolidated statements of financial position

(Million yen)

	As of December 31, 2020	As of September 30, 2021
Assets		
Current assets		
Cash and cash equivalents	25,067	39,155
Trade and other receivables	37,614	28,886
Inventories	25,435	27,816
Other financial assets	222	134
Other current assets	4,194	4,167
Subtotal	92,534	100,159
Assets held for sale	90	—
Total current assets	92,625	100,159
Non-current assets		
Property, plant and equipment	46,293	42,765
Goodwill	18,327	19,517
Intangible assets	14,239	14,369
Right-of-use assets	8,161	9,145
Investments accounted for using equity method	567	540
Other financial assets	17,653	16,956
Retirement benefit asset	269	252
Deferred tax assets	1,336	1,289
Other non-current assets	250	253
Total non-current assets	107,100	105,091
Total assets	199,726	205,250

(Million yen)

	As of December 31, 2020	As of September 30, 2021
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	49,441	40,372
Bonds and borrowings	23,534	11,279
Other financial liabilities	789	488
Lease liabilities	1,589	1,697
Income taxes payable, etc.	2,218	1,163
Provisions	53	70
Other current liabilities	6,637	5,690
Total current liabilities	84,263	60,762
Non-current liabilities		
Bonds and borrowings	8,877	23,329
Other financial liabilities	1,191	1,208
Lease liabilities	8,311	8,709
Retirement benefit liability	5,884	6,181
Provisions	47	44
Deferred tax liabilities	8,738	8,122
Other non-current liabilities	329	453
Total non-current liabilities	33,380	48,050
Total liabilities	117,644	108,812
Equity		
Share capital	12,119	12,119
Capital surplus	14,856	14,811
Retained earnings	51,974	64,916
Treasury shares	(1,720)	(1,960)
Other components of equity	4,853	6,568
Total equity attributable to owners of parent	82,083	96,454
Non-controlling interests	(2)	(16)
Total equity	82,081	96,437
Total liabilities and equity	199,726	205,250

(2) Condensed consolidated statements of profit or loss and comprehensive income

Condensed consolidated statements of profit or loss

(Million yen)

	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2021
Net sales	128,785	145,532
Cost of sales	(103,210)	(110,545)
Gross profit	25,574	34,986
Selling, general and administrative expenses	(19,029)	(19,796)
Other income	1,185	1,092
Other expenses	(3,806)	(805)
Share of profit (loss) of investments accounted for using equity method	(20)	(34)
Operating profit (loss)	3,903	15,443
Finance income	730	2,224
Finance costs	(723)	(764)
Profit (loss) before tax	3,910	16,903
Income tax expense	145	(2,400)
Profit (loss)	4,055	14,503
Profit (loss) attributable to:		
Owners of parent	4,055	14,517
Non-controlling interests	(0)	(14)
Profit (loss)	4,055	14,503
Earnings (loss) per share attributable to owners of parent		
Basic earnings (loss) per share (Yen)	81.20	291.39
Diluted earnings (loss) per share (Yen)	79.15	289.94

Condensed consolidated statements of comprehensive income

(Million yen)

	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2021
Profit (loss)	4,055	14,503
Other comprehensive income		
Items that will not be reclassified to profit or loss		
Net change in fair value of financial assets measured through other comprehensive income	1,339	(818)
Total of items that will not be reclassified to profit or loss	1,339	(818)
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	(1,005)	2,460
Share of other comprehensive income of investments accounted for using equity method	6	(6)
Total of items that may be reclassified to profit or loss	(998)	2,453
Total other comprehensive income	340	1,634
Total Comprehensive income	4,396	16,138
Comprehensive income attributable to:		
Owners of parent	4,396	16,153
Non-controlling interests	0	(14)
Comprehensive income	4,396	16,138

(3) Condensed consolidated statements of changes in equity

(Million yen)

	Equity attributable to owners of parent									
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other components of equity			Total equity attributable to owners of parent	Non-controlling interests	Total equity
					Net change in fair value of financial assets measured through other comprehensive income	Exchange differences on translation of foreign operations	Total other components of equity			
Balance at January 1, 2020	12,119	14,931	42,359	(1,899)	9,955	(2,461)	7,494	75,006	(3)	75,002
Profit (loss)	—	—	4,055	—	—	—	—	4,055	(0)	4,055
Other comprehensive income	—	—	—	—	1,339	(998)	340	340	0	340
Total Comprehensive income	—	—	4,055	—	1,339	(998)	340	4,396	0	4,396
Purchase of treasury shares	—	—	—	(0)	—	—	—	(0)	—	(0)
Disposal of treasury shares	—	(73)	—	142	—	—	—	68	—	68
Dividends of surplus	—	—	(1,747)	—	—	—	—	(1,747)	—	(1,747)
Share-based payment transactions	—	5	—	—	—	—	—	5	—	5
Transfer from other components of equity to retained earnings	—	—	4,245	—	(4,245)	—	(4,245)	—	—	—
Total transactions with owners, etc.	—	(68)	2,498	142	(4,245)	—	(4,245)	(1,674)	—	(1,674)
Balance at September 30, 2020	12,119	14,862	48,913	(1,756)	7,049	(3,460)	3,589	77,727	(3)	77,724
Balance at January 1, 2021	12,119	14,856	51,974	(1,720)	8,416	(3,562)	4,853	82,083	(2)	82,081
Profit (loss)	—	—	14,517	—	—	—	—	14,517	(14)	14,503
Other comprehensive income	—	—	—	—	(818)	2,453	1,635	1,635	(0)	1,634
Total Comprehensive income	—	—	14,517	—	(818)	2,453	1,635	16,153	(14)	16,138
Purchase of treasury shares	—	—	—	(420)	—	—	—	(420)	—	(420)
Disposal of treasury shares	—	(77)	—	180	—	—	—	102	—	102
Dividends of surplus	—	—	(1,496)	—	—	—	—	(1,496)	—	(1,496)
Share-based payment transactions	—	32	—	—	—	—	—	32	—	32
Transfer from other components of equity to retained earnings	—	—	(79)	—	79	—	79	—	—	—
Total transactions with owners, etc.	—	(45)	(1,576)	(239)	79	—	79	(1,782)	—	(1,782)
Balance at September 30, 2021	12,119	14,811	64,916	(1,960)	7,677	(1,109)	6,568	96,454	(16)	96,437

(4) Condensed consolidated statements of cash flows

(Million yen)

	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2021
Cash flows from operating activities		
Profit (loss) before tax	3,910	16,903
Depreciation and amortization	6,333	6,920
Gain on bargain purchase	(804)	—
Impairment losses	612	58
Loss (gain) on sale and retirement of fixed assets	94	(88)
Business structure improvement expenses	2,051	—
Share of loss (profit) of investments accounted for using equity method	20	34
Finance income	(730)	(2,224)
Finance costs	723	764
Decrease (increase) in trade and other receivables	(2,198)	9,090
Decrease (increase) in inventories	(3,358)	(1,598)
Increase (decrease) in trade and other payables	(2,051)	(8,420)
Increase (decrease) in provisions	(18)	12
Increase (decrease) in retirement benefit asset or liability	(188)	235
Other	66	303
Subtotal	4,463	21,990
Interest received	36	23
Dividends received	289	271
Interest paid	(601)	(630)
Income taxes paid	(857)	(3,651)
Income taxes refund	306	43
Net cash provided by (used in) operating activities	3,636	18,047
Cash flows from investing activities		
Proceeds from withdrawal of time deposits	—	109
Purchase of property, plant and equipment	(3,971)	(4,356)
Payments for retirement of property, plant and equipment	(30)	(36)
Proceeds from sale of property, plant and equipment	165	619
Purchase of intangible assets	(366)	(614)
Proceeds from advance payment for finance lease contract	1,500	—
Purchase of investment securities	(95)	(307)
Proceeds from sale of investment securities	6,110	426
Payments for acquisition of subsidiaries	(1,118)	—
Purchase of shares of subsidiaries and affiliates	(213)	—
Other	(142)	(103)
Net cash provided by (used in) investing activities	1,835	(4,263)

(Million yen)

	Nine Months Ended September 30, 2020	Nine Months Ended September 30, 2021
Cash flows from financing activities		
Proceeds from short-term borrowings	11,777	383
Repayments of short-term borrowings	(10,121)	(8,013)
Repayments of lease liabilities	(1,297)	(1,404)
Proceeds from long-term borrowings	159	6,696
Repayments of long-term borrowings	(871)	(4,813)
Proceeds from issuance of bonds	—	9,945
Redemption of bonds	—	(2,840)
Purchase of treasury shares	(0)	(420)
Proceeds from sale of treasury shares	68	93
Dividends paid to owners of parent	(1,740)	(1,490)
Other	(0)	3
Net cash provided by (used in) financing activities	(2,026)	(1,860)
Effect of exchange rate changes on cash and cash equivalents	180	2,165
Net increase (decrease) in cash and cash equivalents	3,626	14,088
Cash and cash equivalents at beginning of period	17,499	25,067
Cash and cash equivalents at end of period	21,125	39,155

(5) Notes to condensed consolidated financial statements

(Notes to going concern assumptions)

Not applicable

(Segment information)

1. Description of reportable segments

The Group's reportable segments are those for which separate financial information is available and regular evaluation by the board of directors is being performed in order to decide the allocation of management resources and to review business results.

The Group sets up divisions by product or service. Each division draws up a plan for comprehensive strategies in Japan and overseas for the products and services it handles, and thereupon develops its business activities.

Accordingly, the Group consists of segments by product and service based on divisions. The three reportable segments are the Industrial Materials segment, Devices segment, and Medical Technologies segment.

The Industrial Materials segment manufactures and sells decorative films, molds, molded plastic products, and metallized papers. The Devices segment manufactures and sells film-based Touch Sensors, gas sensors and others. The Medical Technologies segment manufactures and sells consumable medical products such as medical electrodes, medical chart paper and others and also provides contract development manufacturing services for major medical device manufacturers.

2. Methods of measurement for the amounts of sales and profit (loss) for each reportable segment

The accounting methods for the reportable segments are the same as those used in preparing the consolidated financial statements. Segment profit is based on operating profit, and inter-segment sales is based on current market prices.

3. Information about sales and profit (loss) by reportable segment

The nine months ended September 30, 2020 (January 1, 2020 to September 30, 2020)

(Million yen)

	Reportable segment				Other (Note 1)	Total	Reconcili- ations (Note 2)	Consolidated (Note 3)
	Industrial Materials	Devices	Medical Technologies	Sub-total				
Sales from external customers	35,155	72,743	15,354	123,253	5,531	128,785	—	128,785
Inter-segment sales	1,002	35	0	1,038	1,092	2,130	(2,130)	—
Total	36,157	72,778	15,355	124,291	6,624	130,915	(2,130)	128,785
Segment profit (loss)	440	6,047	678	7,166	(369)	6,796	(2,893)	3,903
Finance income	—	—	—	—	—	—	—	730
Finance costs	—	—	—	—	—	—	—	(723)
Profit (loss) before tax	—	—	—	—	—	—	—	3,910

(Notes) 1. The "Other" category consists of a business segment not included in the reportable segments and includes the Information and Communication, the prescription pharmaceutical manufacturing business, etc.

2. The negative ¥2,893 million of reconciliations in segment profit (loss) includes unallocated corporate expenses, foreign exchange gain (loss), etc. Corporate expenses mainly consist of general and administrative expenses not attributable to any reportable segment.

3. Segment profit (loss) is reconciled with operating profit (loss) recorded in the condensed consolidated statements of profit or loss.

The nine months ended September 30, 2021 (January 1, 2021 to September 30, 2021)

(Million yen)

	Reportable segment				Other (Note 1)	Total	Reconcili- ations (Note 2)	Consolidated (Note 3)
	Industrial Materials	Devices	Medical Technologies	Sub-total				
Sales from external customers	44,291	78,071	17,776	140,139	5,392	145,532	—	145,532
Inter-segment sales	604	10	0	615	975	1,590	(1,590)	—
Total	44,895	78,081	17,776	140,754	6,368	147,123	(1,590)	145,532
Segment profit (loss)	3,969	12,621	740	17,331	(789)	16,541	(1,098)	15,443
Finance income	—	—	—	—	—	—	—	2,224
Finance costs	—	—	—	—	—	—	—	(764)
Profit (loss) before tax	—	—	—	—	—	—	—	16,903

- (Notes)
1. The “Other” category consists of a business segment not included in the reportable segments and includes the Information and Communication, the prescription pharmaceutical manufacturing business, etc.
 2. The negative ¥1,098 million of reconciliations in segment profit (loss) includes unallocated corporate expenses, foreign exchange gain (loss), etc. Corporate expenses mainly consist of general and administrative expenses not attributable to any reportable segment.
 3. Segment profit (loss) is reconciled with operating profit (loss) recorded in the condensed consolidated statements of profit or loss.
 4. The Company finalized the provisional accounting treatment pertaining to business combinations in the fiscal year ended December 31, 2020, and reflected the details of the finalization of the provisional accounting treatment on figures related to the corresponding period of the previous year.

4. Note with regard to changes to reportable segment

From the first quarter ended March 31, 2021, the Information and Communication segment is included in the Other category. Therefore, segment information for the nine months ended September 30, 2020 is stated according to the category following the change.